Clinical Trial Update: Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line Treatment

View source ↗

Summary

A completed clinical trial evaluating fatigue- and hand-foot syndrome-related quality of life in patients with metastatic renal cell carcinoma treated with a fi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Snippet

Sponsor: Pfizer | Conditions: Metastatic Renal Cell Carcinoma | Status: COMPLETED | Results posted: 2021-11-05